Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma

PR Newswire - Press Release

All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here

- GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints -

- Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population undergoing autologous HSCT, including older patients and those who received lenalidomide-containing induction therapies – factors associated with impaired HSPC mobilization -

Read more at prnewswire.com

Related Symbols

Symbol Last Chg %Chg
BLRX 3.04 +0.08 +2.70%
Biolinerx Ltd ADR

Most Popular News

Investor checking market data by SAI SU PAW KA via Shutterstock 1
Forget Nvidia and Broadcom. This Forgotten Retail Stock Is a Top Performer in 2025.
Image of Warren E_ Buffett by Photo Agency via Shutterstock 2
No ‘Intelligence or Emotional Stability’ Required: Warren Buffett Warns Short-Term Markets Are a ‘Voting Machine,’ But Eventually Reflect Reality
Double explosure with businesss charts and financial district of megapolis city by Golden Dayz via Shutterstock 3
Stocks Climb Before the Open on Micron Boost Ahead of U.S. Inflation Data
Doctor holding money by IherPhoto via iStock 4
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside
A Palantir sign displayed on an office building by Poetra_RH via Shutterstock 5
How Much You’d Have If You Bet $10,000 on Palantir Stock in January and 1 Key PLTR Catalyst to Watch in 2026
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot